Breaking News
11 hours ago
Simantini Singh Deo
Climb Bio secures FDA Fast Track designation for budoprutug, its anti-CD19 antibody for primary membranous nephropathy, supported by early clinical remission and safety data.
Simantini Singh Deo
Praxis Precision Medicines, Inc. reports positive Phase 1/2 EMBRAVE trial results with elsunersen, showing significant seizure reduction in pediatric SCN2A epilepsy patients.
Vaibhavi M.
ImmunityBio, Inc. addresses FDA OPDP concerns on ANKTIVA promotions, removes podcast content, and strengthens compliance measures to ensure accurate communication of approved indications.
Vaibhavi M.
Medicus Pharma Ltd. submits optimized Phase 2 trial design to FDA for Teverelix, targeting prevention of recurrent urinary retention in patients with benign prostatic hyperplasia.
Vaibhavi M.